Restenosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 4: | Line 4: | ||
'''Restenosis''' literally means the ''re''occurrence of ''[[stenosis]]''. This is usually restenosis of an [[artery]], or other [[blood vessel]], but possibly any hollow organ that has been "unblocked". This term is common in [[vascular surgery]], [[cardiac surgery]], [[interventional radiology]], or [[interventional cardiology]] following [[angioplasty]], all branches of [[medicine]] that frequently treat stenotic lesions. | '''Restenosis''' literally means the ''re''occurrence of ''[[stenosis]]''. This is usually restenosis of an [[artery]], or other [[blood vessel]], but possibly any hollow organ that has been "unblocked". This term is common in [[vascular surgery]], [[cardiac surgery]], [[interventional radiology]], or [[interventional cardiology]] following [[angioplasty]], all branches of [[medicine]] that frequently treat stenotic lesions. | ||
==Coronary | ==Coronary Restenosis== | ||
There are probably several mechanisms that lead to restenosis. An important one is the [[inflammation|inflammatory]] response, which induces tissue proliferation around an [[angioplasty]] site. | There are probably several mechanisms that lead to restenosis. An important one is the [[inflammation|inflammatory]] response, which induces tissue proliferation around an [[angioplasty]] site. | ||
Cardiologists have tried a number of approaches to decrease the risk of [[restenosis]]. [[Stent|Stenting]] is becoming more commonplace; replacing balloon angioplasty. During the stenting procedure, a metal mesh (stent) is deployed against the wall of the artery revascularizing the artery. Other approaches include local [[radiotherapy]] and the use of [[immunosuppression|immunosuppressive]] drugs, coated onto the stenting mesh. Analogues of [[rapamycin]], such as [[tacrolimus]] (FK-506), [[sirolimus]] and more so [[everolimus]], normally used as immunosuppressants but recently discovered to also inhibit the proliferation of [[blood vessel|vascular]] [[smooth muscle]] cells, have appeared to be quite effective in preventing restenosis in [[clinical trial]]s. [[Antisense]] [[knockdown]] of c-myc, a protein critical for progression of cell replication, is another approach to inhibit cell proliferation in the artery wall and has been through preliminary [[clinical trials]] using [[Morpholino]] oligos. | Cardiologists have tried a number of approaches to decrease the risk of [[restenosis]]. [[Stent|Stenting]] is becoming more commonplace; replacing balloon angioplasty. During the stenting procedure, a metal mesh (stent) is deployed against the wall of the artery revascularizing the artery. Other approaches include local [[radiotherapy]] and the use of [[immunosuppression|immunosuppressive]] drugs, coated onto the stenting mesh. Analogues of [[rapamycin]], such as [[tacrolimus]] (FK-506), [[sirolimus]] and more so [[everolimus]], normally used as immunosuppressants but recently discovered to also inhibit the proliferation of [[blood vessel|vascular]] [[smooth muscle]] cells, have appeared to be quite effective in preventing restenosis in [[clinical trial]]s. [[Antisense]] [[knockdown]] of c-myc, a protein critical for progression of cell replication, is another approach to inhibit cell proliferation in the artery wall and has been through preliminary [[clinical trials]] using [[Morpholino]] oligos. | ||
==Related Chapters== | |||
* [[Drug-eluting stent]] | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Cardiology]] | [[Category:Cardiology]] |
Revision as of 18:34, 28 November 2011
Restenosis Microchapters |
Diagnosis |
---|
Treatment |
Restenosis On the Web |
American Roentgen Ray Society Images of Restenosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-In-Chief:: Bhaskar Purushottam, M.D. [2]
Overview
Restenosis literally means the reoccurrence of stenosis. This is usually restenosis of an artery, or other blood vessel, but possibly any hollow organ that has been "unblocked". This term is common in vascular surgery, cardiac surgery, interventional radiology, or interventional cardiology following angioplasty, all branches of medicine that frequently treat stenotic lesions.
Coronary Restenosis
There are probably several mechanisms that lead to restenosis. An important one is the inflammatory response, which induces tissue proliferation around an angioplasty site.
Cardiologists have tried a number of approaches to decrease the risk of restenosis. Stenting is becoming more commonplace; replacing balloon angioplasty. During the stenting procedure, a metal mesh (stent) is deployed against the wall of the artery revascularizing the artery. Other approaches include local radiotherapy and the use of immunosuppressive drugs, coated onto the stenting mesh. Analogues of rapamycin, such as tacrolimus (FK-506), sirolimus and more so everolimus, normally used as immunosuppressants but recently discovered to also inhibit the proliferation of vascular smooth muscle cells, have appeared to be quite effective in preventing restenosis in clinical trials. Antisense knockdown of c-myc, a protein critical for progression of cell replication, is another approach to inhibit cell proliferation in the artery wall and has been through preliminary clinical trials using Morpholino oligos.